NCT07353671RecruitingPhase 2/3
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 14 Dec 2025
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- West China Hospital
- Diseases
- Head and neck cancer
- NCT number
- NCT07353671
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 60
- From 1 Mar 2026 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.
- Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution).
- Prior Clinical Research: Participation in other interventional clinical studies within the past 3 months and use of any investigational drugs or devices.
Other illness
- Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.).
- Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.
Other
- Investigator Discretion: Subjects judged by the investigator to be unsuitable for participation in this clinical study.
Who the study is looking for
- Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
- Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy.
- Performance Status: Patients with an ECOG Performance Status score of 0 to 2.
- Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sichuan University West China Hospital, Chengdu, Sichuan Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
| Sichuan University West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.